BiotechTube
TRIFARMA

TRIFARMA

Milan, Italy· Est.
trifarma.it
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

TRIFARMA is a private Italian API manufacturer and CDMO with a significant historical legacy dating back to 1958 through its predecessor companies. The company leverages two FDA-approved manufacturing sites in Italy and a strategically important, multi-agency approved (USFDA, PMDA, ANVISA) site in Chennai, India to serve a global customer base. Its business model is built on providing high-quality, niche, and generic APIs, with a strong recent focus on growth through private equity backing (since 2017) and expansion into custom manufacturing and development services.

CardiovascularAnti-infectiveNervous SystemMusculoskeletalDermatologyOphthalmologySteroids

Technology Platform

Integrated API development and manufacturing services platform, emphasizing fast lab-to-industrial scale-up, complex small molecule chemistry, and quality-compliant production across sites in Italy and India.

Opportunities

Full regulatory approval of its Indian site (USFDA, PMDA, ANVISA) opens significant market access to the stringent markets of the US, Japan, and Brazil.
Diversification into non-pharmaceutical CMO work for innovative products provides a new, potentially higher-margin revenue stream alongside its core API business.

Risk Factors

Faces significant regulatory compliance risk across its global manufacturing footprint, where any major inspection finding could disrupt supply.
High competition in the API sector creates persistent pricing pressure, challenging its value proposition.
The business may be vulnerable to customer concentration and geopolitical/supply chain disruptions affecting its Indian operations.

Competitive Landscape

Operates in the highly competitive global API manufacturing and CDMO sector, competing against large Asian producers on cost and against other Western and Indian CDMOs on quality, regulatory track record, and service flexibility. Its key differentiator is its dual-source, EU-India manufacturing base with full regulatory approvals in major markets.

More companies in Small Molecule Drugs →More companies in Italy →